Catherine McBain

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

Roger Stupp, Monika E. Hegi, Thierry Gorlia et al. · The Lancet Oncology · 2014 · 1K citations

Neuro-oncology, Glioma, Medicine +9

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

Martin J. van den Bent, Brigitta G. Baumert, Sara Erridge et al. · The Lancet · 2017 · 392 citations · Full text

Catnon Trial, Treatment Strategies, Radiation Therapy +13

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

Martin J. van den Bent, C. Mircea S. Tesileanu, Wolfgang Wick et al. · The Lancet Oncology · 2021 · 307 citations · Full text

Surgical Oncology, Health Sciences, Glioma +11

X-ray volumetric imaging in image-guided radiotherapy: The new standard in on-treatment imaging

Catherine McBain, Ann Henry, Jonathan Sykes et al. · International Journal of Radiation Oncology*Biology*Physics · 2005 · 182 citations

Adaptive Radiotherapy, New Standard, Health Sciences +9

A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma

R. Rampling, Sharon Peoples, Paul Mulholland et al. · Clinical Cancer Research · 2016 · 160 citations · Full text